Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242512 | 0.88 | ADRA2A (0.35) | ADRA2ASIGMAR1ADRA2BADRA2CADRA1B | |
| SCHEMBL241376 | 0.86 | SIGMAR1 (0.36) | ADRA2ASIGMAR1ADRA2BADRA2CADRA1B | |
| SCHEMBL29775334 | 0.73 | SIGMAR1 (0.41) | ADRA2ASIGMAR1 | |
| SCHEMBL22717802 | 0.73 | SIGMAR1 (0.41) | ADRA2ASIGMAR1 | |
| SCHEMBL196204 | 0.72 | SIGMAR1 (0.44) | SIGMAR1 | |
| SCHEMBL15720982 | 0.69 | TSHR (0.41) | ADRA2ASIGMAR1 | |
| SCHEMBL11706445 | 0.67 | ALDH1A1 (0.41) | SIGMAR1 | |
| SCHEMBL30529399 | 0.67 | ALDH1A1 (0.41) | SIGMAR1 | |
| SCHEMBL71235 | 0.67 | — | — | |
| SCHEMBL30818440 | 0.65 | SIGMAR1 (0.58) | ADRA2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150146-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | NOVARTIS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| WO-2023238078-A1 | (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | VTVX HOLDINGS II LLC | 2021-06-24 | — | — | US | disclosed |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200215073-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | HIGH POINT PHARMACEUTICALS, LLC | 2020-07-09 | — | — | US | disclosed |
| US-10471066-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180071304-A1 | Phenoxy Acetic Acids and Phenyl Propionic Acids as PPAR Delta Agonists | HIGH POINT PHARMACEUTICALS, LLC | 2018-03-15 | — | — | US | disclosed |
| US-9855274-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170216303-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | HIGH POINT PHARMACEUTICALS, LLC | 2017-08-03 | — | — | US | disclosed |
| US-9663481-B2 | Phenoxy acetic acids and phenyl propionic acids as PPARδ agonists | VTV THERAPEUTICS LLC (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007125103-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125105-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007107550-A1 | ADAMANTANE DERIVATIVES FOR THE TREATMENT OF THE METABOLIC SYNDROME | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007101864-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007071766-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007068718-A1 | POLYPEPTIDE PROTRACTING TAGS | NOVO NORDISK A/S (DK) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471066-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | PPARG, PPARA, PPARD | ADRA2A 54/4885SIGMAR1 1906/4885ADRA2B 62/4885 |
| US-20170216303-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | ADRA2A 21/4885SIGMAR1 1730/4885ADRA2B 36/4885 |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | PPARG, PPARA, PPARD | ADRA2A 54/4885SIGMAR1 1906/4885ADRA2B 62/4885 |
| US-20180071304-A1 | Phenoxy Acetic Acids and Phenyl Propionic Acids as PPAR Delta Agonists | PPARG, PPARA, PPARD | ADRA2A 54/4885SIGMAR1 1906/4885ADRA2B 62/4885 |
| US-20200215073-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | ADRA2A 54/4885SIGMAR1 1906/4885ADRA2B 62/4885 |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | ADRA2A 54/4885SIGMAR1 1906/4885ADRA2B 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.